How should a gastrointestinal bleed be managed after intravenous thrombolytic therapy with alteplase?

Management of Gastrointestinal Bleeding After IV Thrombolysis

Stop alteplase immediately if GI bleeding occurs, withhold all antiplatelet and anticoagulant therapy, resuscitate aggressively, and proceed urgently to endoscopy for hemostasis without waiting for coagulation parameters to normalize. 1

Immediate Actions

1. Stop Thrombolytic Therapy

• Discontinue alteplase infusion immediately upon recognition of GI bleeding 1, 2
• Withdraw any remaining drug from the catheter if using central access 2
• Do not delay intervention to complete the infusion

2. Withhold All Antithrombotic Agents

• Stop aspirin and any P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) 3, 4
• The decision to interrupt antiplatelet therapy in the context of ongoing major bleeding is justified despite theoretical thrombotic risks 3
• Critical caveat: This interruption may magnify platelet reactivity and increase thrombotic risk, but active major bleeding takes precedence 3

3. Resuscitation Protocol

• Initiate IV fluid resuscitation immediately 5
• Transfuse red blood cells at hemoglobin threshold of 70-80 g/L (7-8 g/dL) 5
• Avoid overtransfusion which may increase rebleeding risk
• Monitor hemodynamic status continuously

Reversal Strategy

For Alteplase-Associated Bleeding

There is insufficient evidence to support routine use of reversal agents for alteplase-associated GI bleeding 6. However, consider the following on an individual basis:

• Cryoprecipitate: Target fibrinogen level of 1 g/L if administered 7
• Fresh frozen plasma: Only if cryoprecipitate unavailable 7
• Tranexamic acid: Not recommended for GI bleeding outside clinical trials 8
• Platelet transfusions: Should NOT be routinely given 9

Proton Pump Inhibitor Therapy

• Administer high-dose IV PPI immediately 10, 5
• Continue high-dose PPI after endoscopic therapy if ulcer bleeding is confirmed 10

Endoscopic Management

Timing of Endoscopy

• Proceed to endoscopy urgently after resuscitation is initiated 10, 4
• Do NOT delay endoscopy waiting for INR normalization or coagulation parameters to improve 4
• Upper endoscopy should be performed within 24 hours, earlier if hemodynamically unstable 10, 5

Endoscopic Therapy Indications

Endoscopic hemostasis is indicated for 10:

• Active bleeding (spurting or oozing)
• Non-bleeding visible vessel
• Adherent blood clot

Hemostasis Techniques

Use combination therapy for optimal results 10:

• Adrenaline injection (1:10,000 solution, 4-16 mL in quadrants around bleeding point)
• Plus thermal therapy (heater probe 20-30 joules) or mechanical clips
• Combination therapy superior to adrenaline alone for active arterial bleeding 10

Critical Timeframe Considerations

Within 24 Hours Post-Alteplase

• Blood pressure must be maintained <180/105 mmHg for at least 24 hours after alteplase 1
• Risk of any antithrombotic therapy within 24 hours is uncertain 1
• The 24-hour window represents peak bleeding risk from residual fibrinolytic effects

Resumption of Antithrombotic Therapy

For patients requiring antiplatelet therapy for secondary cardiovascular prevention:

• Aspirin: Resume on the day hemostasis is endoscopically confirmed 9

  • Do NOT permanently discontinue aspirin for secondary prevention 8
  • Early resumption (same day after hemostasis) improves outcomes 11

• P2Y12 inhibitors (clopidogrel, etc.): Resume within 5 days maximum after hemostasis 8, 4

  • High risk of thrombosis after 5 days of interruption 8
  • For patients with drug-eluting stents <6 months old, consider even earlier resumption (within 3 days) given extremely high thrombotic risk 4

For patients on anticoagulation:

• Low thrombotic risk: Restart at 7 days after bleeding cessation 8
• High thrombotic risk (mechanical mitral valve, recent VTE <3 months): Consider low molecular weight heparin bridging at 48 hours 8, 4

Common Pitfalls to Avoid

1. Do not give platelet transfusions routinely - no evidence of benefit and may worsen outcomes 9
2. Do not delay endoscopy for "stabilization" - proceed after initial resuscitation 4
3. Do not permanently discontinue aspirin in patients with coronary stents or recent ACS - mortality risk exceeds bleeding risk 11
4. Do not restart both antiplatelet agents simultaneously in DAPT patients - restart aspirin first, then P2Y12 inhibitor 4
5. Do not use vitamin K for DOAC-associated bleeding - ineffective 4

Special Considerations

If Stent Thrombosis Risk is Extremely High

In patients with recent PCI (<6 weeks), particularly with active coronary syndrome, the case example 3 demonstrates that complete interruption of antiplatelet therapy can precipitate fatal stent thrombosis within hours. In such cases:

• Continue aspirin if at all possible even during active bleeding 4
• Withhold only the P2Y12 inhibitor temporarily
• Expedite endoscopic hemostasis to allow earliest possible resumption

Monitoring After Hemostasis

• Observe for rebleeding (occurs in 15-20% after endoscopic therapy) 10
• If rebleeding occurs: repeat endoscopic therapy first 10
• Subsequent rebleeding: consider interventional radiology or surgery 5